Sharvil Patel, managing director of drugmaker Zydus Cadila, tells the Financial Times that Chinese suppliers of raw materials have been price gouging. The Indian company is the largest producer of hydroxychloroquine, an anti-malarial drug that has seen soaring demand since Donald Trump promoted it as a “game-changer” in Covid-19 treatment.
© ChinTell Ltd. All rights reserved.
Exclusively sponsored by HSBC.
The Week in China website and the weekly magazine publications are owned and maintained by ChinTell Limited, Hong Kong. Neither HSBC nor any member of the HSBC group of companies ("HSBC") endorses the contents and/or is involved in selecting, creating or editing the contents of the Week in China website or the Week in China magazine. The views expressed in these publications are solely the views of ChinTell Limited and do not necessarily reflect the views or investment ideas of HSBC. No responsibility will therefore be assumed by HSBC for the contents of these publications or for the errors or omissions therein.